UNICREDIT BANK/CALL/ASTRAZENECA/12000/0.1/19.06.24 | Real-time BOERSE MUENCHEN 11:45:39 2024-05-23 am EDT | ||
| 0.65 EUR | +10.17% |
|
| Current month | +11.32% | ||
| 1 month | +136.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.65 | +10.17% |
| 24-05-22 | 0.59 | -9.23% |
| 24-05-21 | 0.65 | +44.44% |
| 24-05-20 | 0.45 | -6.25% |
| 24-05-17 | 0.48 | -4.00% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 11:45 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HC7FYC |
| ISIN | DE000HC7FYC8 |
| Date issued | 2023-06-19 |
| Strike | 12,000 p |
| Maturity | 2024-06-19 (27 Days) |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.38 € |
|---|---|
| Lowest since issue | 0.009 € |
| Spread | 0.03 € |
| Spread % | 4.48% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.3
USD
Average target price
169.7
USD
Spread / Average Target
+7.87%
- Stock Market
- Warrants
- Warrant
